Disclosed is the use of eprosartan acid for the manufacture of a composition for the treatment of a disorder modulated by blocking angiotensin II (All) receptors selected from the group consisting of hypertension, congestive heart failure, renal failure, and combinations thereof, wherein the composition is for administration to a subject in need thereof to provide a daily dose of 420-480 mg of eprosartan acid. Further disclosed is a pharmaceutical formulation which comprises 420-480 mg of eprosartan acid, and which preferably comprises 450 mg of eprosartan acid； and which optionally further comprises alpha lactose monohydrate as a pharmaceutically acceptable excipient. Also disclosed is a pharmaceutical formulation, suitable as half a dosage strength of the formulation and which comprises 210-240 mg eprosartan acid.
